Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. demonstrates a positive financial outlook, evidenced by a 43% increase in its revenue for the third quarter of 2025, surpassing consensus estimates, alongside a management-guided raise in gross margin expectations to 76-77% for the year. The company's strategic focus on enhancing light adjustable lens (LAL) volumes, coupled with initiatives aimed at expanding the installed base of light delivery devices (LDD), indicates potential for further growth and operational efficiency. Additionally, RxSight's prudent management of operating expenses, alongside an anticipated improvement in margins, reinforces its position for sustainable profitability in the evolving medical technology landscape.

Bears say

RxSight Inc. has reported a decline in monthly utilization of its Light Adjustable Lenses (LALs), dropping to 8.0 units per Light Delivery Device (LDD) in Q3 2025, a decrease from both the previous quarter and the same quarter last year. The company's revenue for the most recent period was $30.3 million, representing a 14% year-over-year decline, with guidance for FY2026 revenue projected at $120-135 million, underperforming compared to existing estimates. Additionally, although operating expenses saw a slight reduction, gross margins are expected to be adversely affected by higher-cost inventory starting in Q2 2026, further contributing to a negative financial outlook.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.